Loading...
Loading...
BDRX| Name | Value |
|---|---|
| Revenues | 234.0K |
| Cost of Revenue | 1,206.5K |
| Gross Profit | -972.5K |
| Operating Expense | 717.5K |
| Operating I/L | -1,889.0K |
| Other Income/Expense | 190.0K |
| Interest Income | 9.0K |
| Pretax | -1,699.0K |
| Income Tax Expense | 168.5K |
| Net Income/Loss | -1,530.5K |
Biodexa Pharmaceuticals Plc is a drug delivery technology company specializing in bio-delivery and biodistribution of medicines. The company's revenue is generated through the development of direct delivery treatments for various brain tumors and long-acting formulations for psychiatric disorders. Their products include MTX110 for gliomas, MTD211 for schizophrenia and major depressive disorder, and MTX223 for long-acting injectable biologic formulations. Additionally, Biodexa offers drug delivery platforms such as Q-Sphera for sustained release, MidaSolve for solubilizing drugs, and MidaCore for targeting disease sites with therapeutic agents.
